Cygenics contract with DOD renewed

By Melissa Trudinger
Wednesday, 16 February, 2005

Singapore-based Cygenics (ASX: CYN) has announced that the US Department of Defence had renewed its screening service contract with the company's US-based subsidiary Cytomatrix.

The renewal of the contract means that the company will receive the more than US$1 million remaining from the original contract which was valued at $1.684 million.

The DOD is using Cytomatrix's three-dimensional cell growth scaffold technology for the production of T cells that can be used to screen vaccine prototypes under development, allowing assessment of in vivo activity in an in vitro system.

Related News

Quitting smoking increases life expectancy even for seniors

Although the benefits of quitting smoking diminish with age, there are still substantial gains...

Stem cell transplants treat blindness in mini pigs

Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...

Sugary drinks raise cardiovascular disease risk, but occasional sweets don't

Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd